摘要
目的探讨微小RNA-141-3p(miR-141-3p)和神经膜蛋白-2(NRSN2)表达水平与肺癌患者骨转移的相关性。方法选取2021年6月~2023年6月在我院就诊的76例肺癌骨转移患者(肺癌骨转移组)和43例肺癌未发生骨转移患者(肺癌未转移组)作为研究对象,另纳入52例体检健康者作为对照组,收集整理其临床基本资料和病理资料。采用qRT-PCR法检测三组血清中miR-141-3p、NRSN2表达水平;TargetScanHuman网站预测miR-141-3p与NRSN2的靶向关系;肺癌骨转移患者血清miR-141-3p与NRSN2表达水平相关性采用Pearson相关分析;Logistic回归分析探讨影响肺癌患者发生骨转移的因素;受试者工作特征(ROC)曲线评价血清miR-141-3p、NRSN2水平诊断肺癌患者是否发生骨转移的临床效能。结果与肺癌未转移组、对照组相比,肺癌骨转移组血清miR-141-3p水平显著降低(P<0.05),与对照组miR-141-3p水平相比,肺癌未转移组显著降低(P<0.05);肺癌骨转移组血清NRSN2水平显著高于未转移组、对照组(P<0.05),未转移组血清NRSN2水平比对照组高(P<0.05)。肺癌骨转移患者血清中miR-141-3p表达水平与肿瘤直径、病理类型、骨转移数目、临床分期和合并其他脏器转移有关(P<0.05),NRSN2水平与肿瘤直径、骨转移数目、临床分期、合并其他脏器转移相关(P<0.05)。Pearson相关分析显示,肺癌骨转移患者血清miR-141-3p与NRSN2表达水平呈现负相关(r=-0.517,P<0.05)。Logistic回归结果显示,NRSN2表达水平、病理类型、临床分期以及合并其他脏器转移均是肺癌患者发生骨转移的独立危险因素(P<0.05);血清miR-141-3p水平是独立保护因素(P<0.05)。血清miR-141-3p、NRSN2水平以及二者联合应用诊断肺癌发生骨转移的曲线下面积(AUC)分别为0.866、0.879、0.941,95%CI分别为0.791~0.921、0.807~0.932、0.882~0.976,二者联合应用诊断肺癌患者发生骨转移的临床价值优于miR-141-3p、NRSN2单独检测(Z二者联合-miR-141-3p=2.937、Z_(
Objective To investigate the correlation between the expression levels of microRNA-141-3p(miR-141-3p)and neurensin-2(NRSN2)and bone metastasis in lung cancer patients.Methods From June 2021 to June 2023,76 lung cancer patients with bone metastasis(the metastasis group)and 43 lung cancer patients without bone metastasis(the non metastasis group)who visited our hospital were selected as the research subjects,and another 52 healthy individuals who underwent physical examination were included as the control group.Their clinical and pathological data were collected and organized.The qRT-PCR method was applied to detect the expression levels of serum miR-141-3p and NRSN2 in the three groups.TargetScanHuman website was applied to predict the targeting relationship between miR-141-3p and NRSN2.The correlation between serum miR-141-3p and NRSN2 expression levels in lung cancer patients with bone metastasis was analyzed using Pearson correlation analysis.Logistic regression was applied to analyze and explore the factors affecting bone metastasis in lung cancer patients.Receiver operating characteristic(ROC)curve was applied to evaluate the clinical efficacy of serum miR-141-3p and NRSN2 levels in diagnosing bone metastasis in lung cancer patients.Results Compared with the non metastasis group and the control group,the serum miR-141-3p level in the metastasis group was obviously reduced(P<0.05),and compared with the control group,that in the non metastatic lung cancer group was obviously reduced(P<0.05).The serum NRSN2 level in the metastasis group was obviously higher than that in the non metastasis group and the control group(P<0.05),while the serum NRSN2 level in the non metastasis group was obviously higher than that in the control group(P<0.05).The expression level of miR-141-3p in the serum of lung cancer patients with bone metastasis was related to tumor diameter,pathological type,number of bone metastases,clinical stage,and the presence of other organ metastases(P<0.05),while the level of NRSN2 was related to tumor
作者
游曼清
何兵
杨扬
罗林城
YOU Manqing;HE Bing;YANG Yang;LUO Lincheng(Department of Respiratory and Critical Care Medicine,Leshan People′s Hospital,Leshan,Sichuan 614000,China)
出处
《临床肺科杂志》
2024年第8期1248-1253,1269,共7页
Journal of Clinical Pulmonary Medicine
